NASDAQ · Biotechnology

ENTX (ENTX) Stock

$2.87 +1.77% NASDAQ: ENTX Healthcare

Valuation

MetricValue
Price$2.87
Market Cap$141.46M
P/E Ratio-4.96
P/B Ratio4.70
P/S Ratio0.00
EPS (TTM)$-0.25
52-Week High$3.92
52-Week Low$0.91
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-84.62%
ROA-68.75%
ROCE-92.31%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.04
Current Ratio3.50

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$0$0$0$0
Operating Profit$-12.0M$-13.0M$-9.0M$-10.0M$-12.0M
Net Profit$-12.0M$-13.0M$-9.0M$-10.0M$-11.0M
EPS$-0.47$-0.45$-0.31$-0.25$-0.25
Op Margin-2139.6%-9752.2%—-5295.6%-27450.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$26.0M$13.0M$12.0M$9.0M$16.0M
Total Liabilities$3.0M$1.0M$1.0M$1.0M$3.0M
Cash$25.0M$12.0M$11.0M$9.0M$7.0M
Borrowings$0$0$0$0$0

Latest News

ENTX Stock On Track For Best Day In Over 5 Years — What’s Driving The Rally? Stocktwits · Jun 22, 2026 Entera Bio Advances Oral Osteoporosis Drug EB613 With Positive FDA Feedback MT Newswires · Jun 22, 2026 Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis GlobeNewswire · Jun 22, 2026 Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026 GlobeNewswire · Jun 16, 2026 ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis) GlobeNewswire · Jun 15, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-9.0M$-12.0M$-7.0M$-7.0M$-7.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$4.0M$0$-1.0M$1.0M$0
Net Cash Flow$16.0M$-13.0M$-1.0M$-2.0M$6.0M
Free Cash Flow$-9.0M$-13.0M$-7.0M$-7.0M$-7.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-15.74%
Quick Ratio7.93
Interest Coverage—
Return 1Y-10.11%
Return 3Y99.29%
Return 5Y-67.69%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABOS $2.27 -0.66% -1.17 $163.60M 0.00%
AGENAgenus Inc. $6.06 +1.34% 3.46 $252.35M 0.00%
ANIX $3.48 -1.14% -8.00 $118.40M 0.00%
HURA $2.09 -2.34% -3.75 $133.10M 0.00%
INO $1.04 +0.97% -2.73 $55.73M 0.00%

About ENTX

ENTX is led by CEO Miranda J. Toledano, employs 18 people, headquartered in IL, publicly traded since 2018.

ENTX stock trades at $2.87 with a market capitalization of $141.46M. The stock is valued at a price-to-earnings (P/E) ratio of -4.96, price-to-book of 4.70, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.91 and $3.92, and currently trades 26.8% below its 52-week high.

On profitability, ENTX generates a return on equity (ROE) of -84.62%, return on capital employed of -92.31%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides